Avacta Group (LON:AVCT) Shares Cross Above 200 Day Moving Average – Should You Sell?

Avacta Group Plc (LON:AVCT)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 67.41 and traded as high as GBX 75. Avacta Group shares last traded at GBX 73.60, with a volume of 1,133,914 shares traded.

Avacta Group Stock Performance

The business’s 50 day simple moving average is GBX 76.06 and its two-hundred day simple moving average is GBX 67.39. The firm has a market capitalization of £332.23 million, a PE ratio of -7.56 and a beta of 1.12. The company has a current ratio of 0.89, a quick ratio of 4.96 and a debt-to-equity ratio of 602.46.

Avacta Group (LON:AVCT) last issued its quarterly earnings data on Tuesday, May 19th. The biotechnology company reported GBX (9.27) EPS for the quarter. The firm had revenue of GBX 11 million during the quarter. Avacta Group had a negative return on equity of 2,929.47% and a negative net margin of 33,961.06%. Research analysts expect that Avacta Group Plc will post -9.9011833 earnings per share for the current fiscal year.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).